Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression for ruling out myelodysplastic syndromes: a prospective validation study
| Autor: | Laura Scheffen, Clara Mariette, José Labarère, Sophie Park, Marie-Christine Jacob, Claude-Eric Bulabois, Tatiana Raskovalova |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Neutrophils Gastroenterology 03 medical and health sciences 0302 clinical medicine Bone Marrow hemic and lymphatic diseases Internal medicine medicine Humans Medical history Prospective Studies Prospective cohort study Aged Peroxidase Aged 80 and over Cytopenia Hematology business.industry Myelodysplastic syndromes General Medicine Middle Aged Flow Cytometry medicine.disease Peripheral blood Confidence interval Myelodysplastic Syndromes 030220 oncology & carcinogenesis Female business 030215 immunology Neutrophil myeloperoxidase |
| Zdroj: | Annals of Hematology. 100:1149-1158 |
| ISSN: | 1432-0584 0939-5555 |
| Popis: | Suspicion of myelodysplastic syndromes (MDS) is the most common reason for bone marrow aspirate in elderly patients. This study aimed to prospectively validate the accuracy for flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression in ruling out MDS. We enrolled 62 consecutive patients who were referred for suspected MDS, based on medical history and peripheral blood cytopenia. The accuracy of intra-individual robust coefficient of variation (RCV) for peripheral blood neutrophil myeloperoxidase expression was assessed with a prespecified 30% threshold. Cytomorphological evaluation of bone marrow aspirate performed by experienced hematopathologists confirmed MDS in 23 patients (prevalence, 37%), unconfirmed MDS in 32 patients (52%, including 3 patients with idiopathic cytopenia of undetermined significance (ICUS)), and was uninterpretable in 7 patients (11%). The median intra-individual RCV values for neutrophil myeloperoxidase expression in peripheral blood were 37.4% (range, 30.7-54.1), 29.2% (range, 28.1-32.1), and 29.1% (range, 24.7-37.8) for patients with confirmed suspicion of MDS, ICUS, and unconfirmed suspicion of MDS, respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink